Table 1.
Baseline characteristics of the cohorta
| Characteristic | HIV-negative controls | Non-HIVAN | HIVAN | P-valueb |
| N | 24 | 7 | 18 | |
| Age (years) | 43.7 ± 11.1 | 44.8 ± 12.3 | 43.5 ± 10.4 | 0.8 |
| Black (%) | 88 | 86 | 89 | 0.8 |
| BUN (mg/dL) | 11.1 ± 3.8 | 40.5 ± 25.7 | 43.6 ± 24.2 | 0.8 |
| Creatinine (mg/dL) | 0.9 ± 0.2 | 2.8 ± 1.6 | 4.1 ± 2.6 | 0.2 |
| eGFR (MDRD) mL/min | 110.8 ± 18 | 46.6 ± 35.8 | 31.5 ± 26.7 | 0.3 |
| Urine protein (g/24 h) | N/A | 7.9 ± 8 | 9.4 ± 7.8 | 0.7 |
| Urine protein (g/g of creatinine) | N/A | 5.5 ± 4.1 | 10.6 ± 7.7 | 0.14 |
| Serum albumin (g/dL) | 4.1 ± 0.5 | 2.5 ± 0.9 | 2.4 ± 0.8 | 0.7 |
| Serum cholesterol (mg/dL) | N/A | 218 ± 99 | 211 ± 99 | 0.9 |
| uNGAL (ng/mL) | 20.1 ± 21.0 | 38.6 ± 22.7 | 191.7 ± 186.9 | 0.04 |
| uNGAL (μg/g of creatinine) | 30.6 ± 39.2 | 94 ± 100.7 | 387.2 ± 339.7 | 0.04 |
| uL-FABP (ng/mL) | 13.9 ± 27.8 | 59.2 ± 27.3 | 169.5 ± 105.5 | 0.01 |
| uL-FABP (μg/g of creatinine) | 14.8 ± 27.7 | 148.9 ± 153.2 | 343.0 ± 186.5 | 0.02 |
| uNAG (mmol/L) | N/A | 5.18 ± 4.19 | 7.1 ± 8.6 | 0.59 |
| uNAG (mmol/g of creatinine) | N/A | 9 ± 7 | 12 ± 8 | 0.41 |
a
N/A, not applicable.
b
P-values are for a comparison of HIV patients with and without HIVAN.